Advanced

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)

Chalmers, J. R.; Simpson, E.; Apfelbacher, C. J.; Thomas, K. S.; von Kobyletzki, L. LU ; Schmitt, J. LU ; Singh, J. A.; Svensson, Åke LU ; Williams, H. C. and Abuabara, K., et al. (2016) In British Journal of Dermatology 175(1). p.69-79
Abstract

This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that... (More)

This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
British Journal of Dermatology
volume
175
issue
1
pages
11 pages
publisher
Wiley-Blackwell
external identifiers
  • Scopus:84982965481
ISSN
0007-0963
DOI
10.1111/bjd.14773
language
English
LU publication?
yes
id
2081e921-107c-4afb-8b32-f3042884a75a
date added to LUP
2016-09-01 16:24:18
date last changed
2016-10-27 09:28:18
@misc{2081e921-107c-4afb-8b32-f3042884a75a,
  abstract     = {<p>This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.</p>},
  author       = {Chalmers, J. R. and Simpson, E. and Apfelbacher, C. J. and Thomas, K. S. and von Kobyletzki, L. and Schmitt, J. and Singh, J. A. and Svensson, Åke and Williams, H. C. and Abuabara, K. and Aoki, V. and Ardeleanu, M. and Awici-Rasmussen, M. and Barbarot, S. and Berents, T. L. and Block, J. and Bragg, A. and Burton, T. and Bjerring Clemmensen, K. K. and Creswell-Melville, A. and Dinesen, M. and Drucker, A. and Eckert, L. and Flohr, C. and Garg, M. and Gerbens, L. A A and Graff, A. L B and Hanifin, J. and Heinl, D. and Humphreys, R. and Ishii, H. A. and Kataoka, Y. and Leshem, Y. A. and Marquort, B. and Massuel, M. A. and Merhand, S. and Mizutani, H. and Murota, H. and Murrell, D. F. and Nakahara, T. and Nasr, I. and Nograles, K. and Ohya, Y. and Osterloh, I. and Pander, J. and Prinsen, C. and Purkins, L. and Ridd, M. and Sach, T. and Schuttelaar, M. L A and Shindo, S. and Smirnova, J. and Sulzer, A. and Synnøve Gjerde, E. and Takaoka, R. and Vestby Talmo, H. and Tauber, M. and Torchet, F. and Volke, A. and Wahlgren, C. F. and Weidinger, S. and Weisshaar, E. and Wollenberg, A. and Yamaga, K. and Zhao, C. Y. and Spuls, P. I.},
  issn         = {0007-0963},
  language     = {eng},
  month        = {07},
  number       = {1},
  pages        = {69--79},
  publisher    = {ARRAY(0x8417330)},
  series       = {British Journal of Dermatology},
  title        = {Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)},
  url          = {http://dx.doi.org/10.1111/bjd.14773},
  volume       = {175},
  year         = {2016},
}